분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-09-24 07:12:48 , Hit : 829
 UPDATE 2-Gilead experimental drug fights all forms of hep C: data


Markets  |  Mon Sep 21, 2015 12:48pm EDT
Related:  Stocks,  Regulatory News,  Markets,  Healthcare  

By Natalie Grover

(Reuters) - Gilead Sciences Inc is edging closer to the approval of the first drug to fight all forms of hepatitis C as the drugmaker's experimental combination showed high rates of effectiveness in four late-stage studies.

The trials were evaluating a once-daily, fixed-dose combination of the drugmaker's approved hep C blockbuster, Sovaldi, with experimental NS5A inhibitor velpatasvir.

The combination is Gilead's second single-tablet treatment for the viral infection. Harvoni, its approved drug, targets the most common form - genotype 1 infections.

The main goal of each trial testing the experimental combination was to achieve a cure 12 weeks after the completion of therapy.

Of the 1,053 patients treated with the drug for 12 weeks in three trials, 98 percent were cured.

Data from the fourth trial, in more advanced and weaker patients, showed higher cure rates when patients also received ribavirin, an older antiviral.

Treatment-related side effects caused the death of nine patients in the trial, the company said.

The combination reduces the need for genotyping and potential confusion about which regimen works in which patients, UBS AG's Matthew Roden said.

Gilead's twin blockbuster hep C offerings, Sovaldi and Harvoni, brought in combined sales of about $4.9 billion last quarter.

Harvoni is expected to remain the treatment of choice in genotype 1, given it is taken for eight weeks, JP Morgan's Cory Casimov said.

Gilead's Sovaldi/velpatasvir combination demonstrated significant cure rates after 12 weeks.

William Blair's John Sonnier said the combination along with Gilead's GS-9857 could decrease treatment to six weeks while maintaining pan-genotypic potency.

In July, the FDA approved two new treatments for less common forms of hep C - AbbVie Inc's Technivie for genotype 4 and Bristol-Myers Squibb Co's Daklinza for genotype 3.

"A single, pan-genotypic approach may be particularly attractive in regions outside the United States where genotyping is less routine (or not possible)," Casimov said.

The Sovaldi/velpatasvir combination bodes well for Gilead to penetrate markets outside the United States, where non-genotype 1 hep C is more prevalent, Sonnier added.

The Foster City, California-based drugmaker plans to file marketing applications for the combination by the fourth quarter.

The company's stock, however, fell 2 percent after Hillary Clinton said she will propose a plan to take on specialty drug price gouging. S&P 500 Healthcare index was down 1 pct. (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva and Don Sebastian)







907    [바이오토픽] 2015 노벨화학상: 세포의 비밀을 밝혀낸 화학자들  이성욱 2015/10/08 1892
906   바이오통신원 [바이오토픽] 2015 노벨생리학상을 휩쓴 기생충약 개발자들  이성욱 2015/10/06 1780
905   노벨 생리의학상 유감(有感)  이성욱 2015/10/06 813
904   혁신적인 폐암 면역치료제를 승인한 FDA  이성욱 2015/10/06 992
903   지방간과 흉터가 유전과 관련되어 있다?  이성욱 2015/10/05 1020
902   바이러스가 살아있다는 증거를 더한 연구  이성욱 2015/10/05 948
901   화성의 물에서 생명체를 찾는 것의 어려움  이성욱 2015/10/01 982
900   CRISPR/Cas9의 대안: CRISPR/Cpf1  이성욱 2015/09/29 1415
  UPDATE 2-Gilead experimental drug fights all forms of hep C: data  이성욱 2015/09/24 829
898   RNA-Based Therapeutics and Vaccines  이성욱 2015/09/21 1023
897   힝스턴 그룹, 인간배아 유전자 편집의 윤리적 정당성 인정  이성욱 2015/09/16 1171
896   혈액 암과 면역세포의 DNA 편집의 관계  이성욱 2015/09/14 986
895   아스피린이 암의 면역요법 효과 증대  이성욱 2015/09/08 874
894   처음으로 밝혀진 수면부족과 감기 간의 관련성  이성욱 2015/09/03 904
893   알츠하이머 질환에 대한 항체약물의 가능성  이성욱 2015/07/30 1050
892   DNA 앰블런스  이성욱 2015/07/30 995
891   유전자 넉아웃을 보상하는 또 다른 유전자  이성욱 2015/07/30 1231
890   FDA approves hepatitis C drugs from AbbVie, Bristol-Myers  이성욱 2015/07/28 918
889   항-PD-1 항체에 저항성을 보이는 기작  이성욱 2015/07/28 1118
888   항체 함암제를 테스트할 수 있는 인간화 생쥐 모델  이성욱 2015/07/28 1361

[이전 10개] [1]..[11][12][13][14][15][16][17][18] 19 [20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN